The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Share News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,438.00
Bid: 1,436.00
Ask: 1,442.00
Change: 0.00 (0.00%)
Spread: 6.00 (0.418%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,438.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Indivior puts biggest investor on board in overhaul

Wed, 24th Mar 2021 07:56

(Sharecast News) - Indivior has given Scopia Capital, its biggest investor, a place on its board as part of a governance overhaul by the prescription drugs group.
Jerome Lande, a partner at Scopia, will be one of four new non-executive directors. Scopia is Indivior's biggest shareholder with a 16.9% stake in the company.

Lande will be joined on the board by Juliet Thompson, a former investment banker and adviser to drugs groups; former GlaxoSmithKline executive Jo Le Couillard; and pharmaceutical industry veteran Mark Stejbach.

They all join with immediate effect and will replace Daniel Tasse, Lorna Parker, Dan Phelan and Tom McLellan, who all joined the company when it was split off from Reckitt Benckiser in 2014. Tasse and Parker will step down at the next annual meeting, Phelan will leave by the end of 2022 and McLellan will serve until November 2023.

The directors presided over a mis-selling scandal that cost Indivior $600m of fines and resulted in its former chief executive, Shaun Thaxter, going to prison in the US. Former chief financial officer Mark Crossley replaced Thaxter in June and Graham Hetherington joined as chairman in November

In November, Indivior settled a case with the US Department of Justice that accused the company of fraudulently claiming its Suboxone Film was better and safer than other opioid addiction treatments. The company also referred patients to doctors it knew to be prescribing opioids in a careless manner, the indictment said.

"After a period of significant strategic change and decisive actions to better position Indivior for future value creation ... we are pleased to welcome the new NEDs to the board," Hetherington said. "Indivior's board and leadership team are committed to engaging actively with shareholders to better understand their views and we fully support and look forward to Jerome's perspectives as a representative of our largest shareholder."

With Lande on the board, Scopia has agreed not to exercise more than 20% of voting rights in the company "from time to time", to vote for ordinary resolutions recommended by the board and to vote consistently with board recommendations.

Indivior is looking for another, preferably female, non-executive director and will draw up a shortlist in consultation with Scopia.









More News
30 Jun 2021 12:17

LONDON MARKET MIDDAY: Stocks slide ahead of US ADP jobs report

LONDON MARKET MIDDAY: Stocks slide ahead of US ADP jobs report

Read more
30 Jun 2021 10:41

Indivior raises profit and revenue guidance after strong start to year

Indivior raises profit and revenue guidance after strong start to year

Read more
30 Jun 2021 09:02

LONDON MARKET OPEN: Indivior shines after upgrading guidance

LONDON MARKET OPEN: Indivior shines after upgrading guidance

Read more
30 Jun 2021 07:58

LONDON MARKET PRE-OPEN: Dividend contrast from Dixons and Stagecoach

LONDON MARKET PRE-OPEN: Dividend contrast from Dixons and Stagecoach

Read more
30 Jun 2021 07:35

Indivior lifts 2021 guidance after better-than-expected H1

(Sharecast News) - Opioid addiction treatment maker Indivior lifted its 2021 guidance on Wednesday following a better-than-expected business performance through the first half of the year.

Read more
21 Jun 2021 09:34

BROKER RATINGS: UBS cuts Rio Tinto to Sell; Morgan Stanley ups Ocado

BROKER RATINGS: UBS cuts Rio Tinto to Sell; Morgan Stanley ups Ocado

Read more
8 Jun 2021 14:27

IN BRIEF: Indivior secures license for cannabis disorder treatment

IN BRIEF: Indivior secures license for cannabis disorder treatment

Read more
8 Jun 2021 12:36

Indivior joins forces with France's Aelis on treatment for cannabis use disorder

(Sharecast News) - Indivior said on Tuesday that it has teamed up with French biotechnology group Aelis to advance the clinical development of a treatment for cannabis use disorder.

Read more
8 Jun 2021 12:36

Indivior teams up with Aelis on treatment for cannabis use disorder

(Sharecast News) - Indivior said on Tuesday that it has teamed up with French biotechnology group Aelis to advance the clinical development of a treatment for cannabis use disorder.

Read more
6 May 2021 17:50

UPDATE: Pay comes under spotlight at BAE, Indivior and Rio Tinto AGMs

UPDATE: Pay comes under spotlight at BAE, Indivior and Rio Tinto AGMs

Read more
29 Apr 2021 16:11

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
29 Apr 2021 12:26

Indivior maintains 2021 guidance as first quarter revenue increases

Indivior maintains 2021 guidance as first quarter revenue increases

Read more
28 Apr 2021 10:47

Indivior says US filings "administrative", no new Suboxone settlements

Indivior says US filings "administrative", no new Suboxone settlements

Read more
22 Apr 2021 16:10

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
24 Mar 2021 10:11

Indivior revamps board after accord with biggest shareholder Scopia

Indivior revamps board after accord with biggest shareholder Scopia

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.